1H-3-BENZAZEPIN-7-OL, 5-(7-BENZOFURANYL)-8-CHLORO-2,3,4,5-TETRAHYDRO-3-METHYL-, (5S)-
Kita-kyushu Lung Cancer Antigen 1, Human
National Cancer Institute (NCI)Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
8 Active assets in the Kita-kyushu Lung Cancer Antigen 1, Human cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine National Cancer Institute (NCI) | Phase 1 | CC |
Cyclophosphamide National Cancer Institute (NCI) | Phase 1 | CC |
Famotidine National Cancer Institute (NCI) | Phase 1 | CC |
FALLYPRIDE National Cancer Institute (NCI) | Phase 1 | CC |
INDOMETACINUM National Cancer Institute (NCI) | Phase 1 | CC |
Zofran National Cancer Institute (NCI) | Phase 1 | CC |
Meperidine National Cancer Institute (NCI) | Phase 1 | CC |
Kk-Lc-1 Tcr National Cancer Institute (NCI) | Phase 1 | NR |
Same molecule, other indications
1H-3-BENZAZEPIN-7-OL, 5-(7-BENZOFURANYL)-8-CHLORO-2,3,4,5-TETRAHYDRO-3-METHYL-, (5S)- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →